RCUS

Summit Therapeutics is expanding its investigational drug ivonescimab beyond non-small cell lung cancer into colorectal and bladder cancer indications. The company has initiated phase III trials for metastatic colorectal cancer and phase II/III studies for advanced bladder cancer.

Strategic partnerships with AstraZeneca, GSK, and Arcus Biosciences are evaluating ivonescimab in combination with other cancer therapies, with AstraZeneca committing $2 billion in investment. An FDA decision on ivonescimab for EGFR-mutated NSCLC is expected by November 2026.

Biogen is expected to report Q3 2026 earnings on October 28 with a consensus EPS estimate of $2.04 per share (down 57.6% YoY) and revenues of $2.59 billion (up 2% YoY). With a positive Earnings ESP of +1.81% and Zacks Rank #3 (Hold), the company appears positioned to beat consensus estimates. Biogen has beaten EPS estimates in all four of the last quarters.